Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 477

Similar articles for PubMed (Select 16791448)

1.

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

Brady MS, Brown K, Patel A, Fisher C, Marx W.

Ann Surg Oncol. 2006 Aug;13(8):1123-9. Epub 2006 Jun 21.

PMID:
16791448
2.

Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.

Chin-Lenn L, Temple-Oberle C, McKinnon JG.

Plast Surg (Oakv). 2015 Spring;23(1):25-30.

PMID:
25821769
3.

[Adverse systemic reactions in intensive care medicine after isolated limb perfusion with melphalan and hyperthermia: case report].

Arruda FO, Guimarães HP, Falcão LF, Leal PH, Lopes RD, Santos ID, Amaral JL.

Rev Bras Ter Intensiva. 2006 Dec;18(4):423-6. Portuguese.

PMID:
25310560
4.

Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.

Muilenburg DJ, Beasley GM, Thompson ZJ, Lee JH, Tyler DS, Zager JS.

Ann Surg Oncol. 2015 Feb;22(2):482-8. doi: 10.1245/s10434-014-4072-0. Epub 2014 Sep 6.

PMID:
25192683
5.

Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.

Rashid OM, Sloot S, Zager JS.

Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1355-64. doi: 10.1517/17425255.2014.951330. Epub 2014 Sep 1. Review.

PMID:
25176398
6.

A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Beasley GM, Speicher P, Augustine CK, Dolber PC, Peterson BL, Sharma K, Mosca PJ, Royal R, Ross M, Zager JS, Tyler DS.

Ann Surg Oncol. 2015 Jan;22(1):287-94. doi: 10.1245/s10434-014-3887-z. Epub 2014 Aug 22.

7.

Quality of life after isolated limb infusion for in-transit melanoma of the extremity.

Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS.

Ann Surg Oncol. 2015 May;22(5):1694-700. doi: 10.1245/s10434-014-3979-9. Epub 2014 Aug 14.

PMID:
25120251
8.

Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation.

Podleska LE, Poeppel T, Herbrik M, Dahlkamp L, Grabellus F, Taeger G.

World J Surg Oncol. 2014 Apr 1;12:81. doi: 10.1186/1477-7819-12-81.

9.

Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.

Coventry BJ, Kroon HM, Giles MH, Henderson M, Speakman D, Wall M, Barbour A, Serpell J, Paddle P, Coventry AG, Sullivan T, Smithers BM.

J Surg Oncol. 2014 Jun;109(8):780-5. doi: 10.1002/jso.23590. Epub 2014 Mar 15.

PMID:
24634160
10.

Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Lidsky ME, Speicher PJ, Jiang B, Tsutsui M, Tyler DS.

J Surg Oncol. 2014 Mar;109(4):357-65. doi: 10.1002/jso.23502. Epub 2013 Nov 20. Review.

PMID:
24522940
11.

Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.

Kroon HM, Huismans AM, Kam PC, Thompson JF.

J Surg Oncol. 2014 Mar;109(4):348-51. doi: 10.1002/jso.23553. Review.

PMID:
24522939
12.

Isolated limb perfusion with melphalan for melanoma.

Nieweg OE, Kroon BB.

J Surg Oncol. 2014 Mar;109(4):332-7. doi: 10.1002/jso.23558. Epub 2014 Jan 14. Review.

PMID:
24421252
13.

Isolated limb infusion: technical aspects.

Kroon HM, Huismans A, Waugh RC, Kam PC, Thompson JF.

J Surg Oncol. 2014 Mar;109(4):352-6. doi: 10.1002/jso.23540. Epub 2013 Dec 24. Review.

PMID:
24374797
14.

Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.

Steinman J, Ariyan C, Rafferty B, Brady MS.

J Surg Oncol. 2014 Apr;109(5):405-9. doi: 10.1002/jso.23519. Epub 2013 Dec 7.

PMID:
24318953
15.

Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion.

Reintgen M, Reintgen C, Nobo C, Giuliano R, Shivers S, Reintgen D.

Cancers (Basel). 2010 Feb 10;2(1):43-50. doi: 10.3390/cancers20100043.

16.

Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.

Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS.

J Surg Oncol. 2014 Apr;109(5):434-9. doi: 10.1002/jso.23501. Epub 2013 Nov 19.

PMID:
24249545
17.

Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.

Wong J, Chen YA, Fisher KJ, Beasley GM, Tyler DS, Zager JS.

Ann Surg Oncol. 2014 Feb;21(2):650-5. doi: 10.1245/s10434-013-3336-4. Epub 2013 Oct 26.

PMID:
24162840
18.

Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit.

Giles MH, Coventry BJ.

Cancer Manag Res. 2013 Aug 20;5:243-9. doi: 10.2147/CMAR.S45746. eCollection 2013.

19.

Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma.

Speicher PJ, Beasley GM, Jiang B, Lidsky ME, Palmer GM, Scarbrough PM, Mosca PJ, Dewhirst MW, Tyler DS.

Ann Surg Oncol. 2014 May;21(5):1435-40. doi: 10.1245/s10434-013-3222-0. Epub 2013 Aug 28.

20.

Predicting disease progression after regional therapy for in-transit melanoma.

Lidsky ME, Turley RS, Beasley GM, Sharma K, Tyler DS.

JAMA Surg. 2013 Jun;148(6):493-8. doi: 10.1001/jamasurg.2013.695.

PMID:
23558401
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk